Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Taranabant CB1 Receptor Inverse Agonist for Management of Obe

Drug (Brand/Generic)

Taranabant

Company/Licensee

Merck & Co

Therapy Class

Selective cannabinoid-1 (CB1) receptor inverse agonist

Product Description

Binds to the CB1 endocannabinoid receptor

Current Indication

Treatment of obesity in combination with dietary control

Market Sector

Nutrition

Development Status

Cancelled
Expand

Go Top